IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announced today that Hanan Sboul, Secretary General of the Jordanian Association of Pharmaceutical Manufacturers, is taking over the position of IGBA Chair for 2020 from Jim Keon, President of the Canadian Generic Pharmaceutical Association and Biosimilars Canada.
The International Generic and Biosimilar Medicines Association (IGBA) welcomes the adoption by the International Council for Harmonization (ICH) of a new topic proposal on Bioequivalence for ImmediateRelease Solid Oral Dosage Forms (M13)i . The ICH Assembly approved the Concept Paper Outline in their November Singapore meeting with the establishment without delay of a new Working Group to initiate work on finalizing the concept paper and business plan for this new topic.
Since September 2018 the World Intellectual Property Organization (WIPO) has hosted the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) patent database Pat-INFORMEDi on its website. This database is simply a posting of unverified patent information provided directly by originator pharmaceutical companies. WIPO specifically exempts itself and IFPMA member companies from any and all liability for the provision of false or inaccurate informationii .
- WHO signs MoU with International Generic and Biosimilar Medicines Association to promote access (October 2019)
- IGBA recommendations for action to support a sustainable global pharmaceutical market for continued patient access worldwide to safe, effective and high-quality medicines (October 2019)
- The positive impact that generic and biosimilar medicines have on patients and health systems (October 2019)
- Op-ed: Trade agreement drug monopoly is obsolete given faster, better drug discovery